Skip to main content
34928 search results for:

Cancer Immunotherapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-04-2024 | Gastric Cancer | Online First

    Biomarker-oriented chemo-immunotherapy for advanced gastric cancer

    The biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of …

  2. 01-05-2024 | Cancer Immunotherapy | ReviewPaper

    Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

    Drug repositioning or repurposing has gained worldwide attention as a plausible way to search for novel molecules for the treatment of particular diseases or disorders. Drug repurposing essentially refers to uncovering approved or failed compounds …

  3. Open Access 01-12-2024 | Cancer Immunotherapy | ReviewPaper

    Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

    Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds. The tumor microenvironment …

  4. Open Access 01-12-2024 | Checkpoint Inhibitors | Letter

    Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy

    The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis to investigate the characteristics …

  5. Open Access 01-12-2024 | Pancreatic Cancer | OriginalPaper

    Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

    The advent of immunotherapy marks a transformative epoch in cancer treatment, yielding unprecedented clinical advantages for patients [ 1 ]. Nevertheless, limited response rates and the inability to predict clinical efficacy obstacle their further …

  6. Open Access 01-12-2024 | NSCLC | OriginalPaper

    Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)

    Besides programmed death ligand 1 (PD-L1) expression, rapid, cost-effective and validated scores or models are critical for the prognosis and prediction of patients received immune checkpoint inhibitors (ICIs). In this retrospective study, 182 …

  7. 01-05-2024 | OriginalPaper

    Correlation between changes in nutritional status and tumor response in patients receiving immunotherapy for lung cancer (NUTIMMUNO study)

    Malnutrition is a common condition in lung cancer, and it is an independent prognostic factor. The main objective of this study was to determine whether an early improvement at 3 months in the nutritional status (NS) of patients undergoing immune …

  8. Open Access 01-12-2024 | Biomarkers | ReviewPaper

    CTLs heterogeneity and plasticity: implications for cancer immunotherapy

    Cytotoxic T lymphocytes (CTLs) play critical antitumor roles, encompassing diverse subsets including CD4+, NK, and γδ T cells beyond conventional CD8+ CTLs. However, definitive CTLs biomarkers remain elusive, as cytotoxicity-molecule expression …

  9. 16-04-2024 | Checkpoint Inhibitors | Online First

    Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations

    Lung cancer stands as the most prevalent and fatal malignancy worldwide, with non-small cell lung cancer (NSCLC) accounting for over 80% of cases. In China, both new diagnoses and fatalities from lung cancer top the charts among malignant tumors [ …

  10. 19-02-2024 | Esophageal Cancer | ReviewPaper

    Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?

    This paper shines a light on the exciting progress being made in using immunotherapy to treat advanced gastroesophageal cancers. The positive results from trials using drugs like Pembrolizumab and Nivolumab are certainly encouraging and open new …

  11. 20-04-2024 | Tracheostomy | Online First

    Velopalatine and Bilateral Vocal Cord Paralysis Associated with Atezolizumab Treatment: A Severe and Previously Undocumented Side Effect in Cancer Immunotherapy

    Adverse effects of immunotherapeutic treatments like atezolizumab remain largely unknown due to limited experience. We present a 65-year-old man with sudden dyspnea and other symptoms, implicating immunotherapy. Prompt intervention and suspension …

  12. Open Access 01-12-2024 | NSCLC | ReviewPaper

    Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

    Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types, non-small cell lung cancer (NSCLC) …

  13. 25-04-2024 | SCLC | Online First

    Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy

    Small-cell lung cancer (SCLC) constitutes approximately 13 to 15% of the total global incidence of lung cancer [ 1 ]. Approximately 70% of patients with SCLC present with the extensive stage of the disease at initial diagnosis, contributing to poor …

  14. Open Access 01-04-2024 | Pancreatic Cancer | ReviewPaper

    Clinical immunotherapy in pancreatic cancer

    Pancreatic cancer remains a challenging disease with limited treatment options, resulting in high mortality rates. The predominant approach to managing pancreatic cancer patients continues to be systemic cytotoxic chemotherapy. Despite substantial …

  15. 01-05-2024 | Gastric Cancer | OriginalPaper

    Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

    Suppression of the cGAS-STING pathway is an immune escape mechanism in cancer cells. The critical role of this pathway in gastric cancer (GC) is not fully understood. Herein, we evaluated the effect of the interferon-gamma (IFN-gamma), STING …

  16. Open Access 01-05-2024 | Pancreatic Cancer | OriginalPaper

    DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy

    Gastric cancer, ranked as the sixth most prevalent cancer globally, is the third leading cause of cancer-related mortality [ 1 ], and is widely recognized as one of the most challenging malignancies to treat. Although early gastric cancer exhibits …

  17. Open Access 01-12-2024 | Cancer Immunotherapy | OriginalPaper

    Decision-making and autonomy among participants in early-phase cancer immunotherapy trials: a qualitative study

    Advances in cancer care depend on evidence derived from clinical trials (CTs) to help practitioners and patients make informed treatment decisions. However, less than 5% of adult patients with cancer participate in CTs [ 1 ] and many trials suffer …

  18. Open Access 01-12-2024 | NSCLC | ReviewPaper

    Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients

    In recent years, various types of immunotherapy, particularly the use of immune checkpoint inhibitors targeting programmed cell death 1 or programmed death ligand 1 (PD-L1), have revolutionized the management and prognosis of non-small cell lung …

  19. Open Access 01-12-2024 | Colorectal Cancer | OriginalPaper

    Heterogeneous expression of ARID1A in colorectal cancer indicates distinguish immune landscape and efficacy of immunotherapy

    AT-rich interaction domain 1A (ARID1A) functions as a subunit of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex and ranks among the most frequently mutated genes in colorectal cancer (CRC) (9.3–11.1%) [ 1 – 3 ]. The …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.